{"disease":{"id":"hereditary-angioedema-type-i-and-ii","name":"hereditary angioedema type i and ii"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03828279","title":"Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II","phase":"","overall_status":"UNKNOWN","enrollment_count":220,"lead_sponsor_name":"HAE Global Registry Foundation","has_results":false},{"nct_id":"NCT06343779","title":"Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Pharvaris Netherlands B.V.","has_results":false},{"nct_id":"NCT02316353","title":"A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT04618211","title":"Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Pharvaris Netherlands B.V.","has_results":true},{"nct_id":"NCT05047185","title":"Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Pharvaris Netherlands B.V.","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}